Ethical and regulatory considerations for safeguarding participants in bispecific antibody clinical trials, and best practices designed to optimize their success.
Sharad Adekar, MD, PhD, CIP
Advertisement
Senior Medical Chair at WCG’s IRB in Puyallup, Washington
Articles by Sharad Adekar, MD, PhD, CIP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: AstraZeneca Expands Immunotherapy Reach as Thermo Fisher’s $8.8B Deal Signals New Phase for Digital Trials
2
Engineered Bispecific Antibodies: Regulatory, Ethical, and Best Practice Guidelines
3
MATTERHORN Trial Findings Signal Paradigm Shift in Early Gastric Cancer Care
4
ACT Brief: AI, Equity, and Innovation Drive Clinical Research Forward
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
